Companies › Kyverna Therapeutics
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Immunology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| KYV-101 anti-CD19 chimeric antigen receptor T-cell therapy | CD19 | Phase 2 | Multiple Sclerosis, Primary Progressive; Myasthenia Gravis; Idiopathic Inflammatory Myopathies | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06152172 | KYV-101 | Phase 1 | Idiopathic Inflammatory Myopathies | Immunology | Feb 2027 |
| NCT06384976 | KYV-101 | Phase 2 | Multiple Sclerosis, Primary Progressive | Neurology | Apr 2027 |
| NCT06193889 | KYV-101 | Phase 2 | Myasthenia Gravis | Neurology | Sep 2027 |
Cash and short-term investments of $199m on 2026-06-30; operating cash outflow about $166m a year; runway about 14 months at that burn, to Sep 2027; 1 of 2 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
Held by 4 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Autolus Cabaletta Bio Hope Biosciences Research Foundation Shanghai Ming Ju Biotechnology Fate Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.